Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is calling on the public to help in the fight against prescription drug abuse by taking part in National Prescription Drug Takeback Day on Saturday, October 26th, 2024. Twice a year, drug takeback days are reserved for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,550 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misu.

Walgreens Collects More than 6-Million Pounds of Unused Prescription Medication, Seeks the Public's Help for National Drug Takeback Day

AGNC Investment

Big 5 Sporting Goods

Berry Petroleum Corp.

CIM Commercial Trust

Horizon Technology Finance

Icahn Enterprises

Natural Health Trends

New York Mortgage Trust

Oxford Square Capital

Prospect Capital

B. Riley Financial

TFS Financial

Uniti Group

Xerox

24/7 Wall Street Insights NASDAQ was founded in 1971 as an automated quote stock exchange alternative to the New York Stock Exchange, and now has more listings than the NYSE.

These 15 Stocks Are Among the Top Dividend Payers on the NASDAQ

Walgreens Boots Alliance Inc. NASDAQ: WBA is a leading global retail pharmacy and healthcare company. The stock is trading down 60% from its 52-week high and with a stock performance down 58.5% year-to-date (YTD).

Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy

Is Walgreens' Ultra-High-Yield Dividend in Jeopardy Again?

Aptiv

Dayforce Inc

International Paper

Super Micro Computer

Investors "short" stocks that they think will fall in price, profiting off the loss using a sometimes risky buying maneuver.

These Are the 5 Most Shorted Stocks in the S&P 500 Index. The Bears Are Wrong About 1 of Them.

Walgreens Boots Alliance's recent results have sparked investor optimism, providing a lifeline to the sagging stock. The upside sales surprise in Q4 FY24 worked in WBA's favor, but the guidance indicates that sales will remain muted in FY25. The EPS outlook is also disappointing, indicating that WBA's attractive P/E ratio needs to be taken with a pinch of salt and that its big dividends come at a risk.

Walgreens: Latest Financials Aren't Comforting Enough

Pfizer

Income investors have both good and not-so-good options in the healthcare sector.

1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid

This pharmacy leader could be the comeback story of 2025.

Is Walgreens Boots Alliance Stock a Buy?

CVS Health

If you buy these stocks, you might be in for serious disappointment when they underperform.

2 "Safe" Healthcare Stocks That Are Anything But

The company's earnings provided some hope for a turnaround -- but there's a long way to go.

Why Walgreens Boots Alliance Rallied This Week

Franklin Resources

Crown Castle International

Healthpeak Properties Inc

Dow Inc

Ford Motor Company

KeyCorp

LyondellBasell Industries

Altria

Realty Income Corp

Simon Property Group

AT&T

Truist Financial

Verizon

The Standard & Poor's 500 Index was created by credit agency Standard & Poor's in 1957.

These 15 Stocks Are Among the Top Dividend Payers in the S&P 500

Has Walgreens stock finally put in a bottom?

Walgreens Rallies on Store Closure Plan. Is the Stock a Buy Now?

Walgreens recently reported its Q4'24 results (fiscal ends in August), with revenue and earnings exceeding our expectations. The company reported revenue of $37.5 billion and adjusted earnings of $0.39 per share, compared to our estimates of $34.9 billion, and $0.38, respectively.

Why Did Walgreens Stock Rise 20%?

There's more to any investment than a single number.

Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?

I initially pitched a short on Walgreens with a price target of $8.35, but the stock reached that target faster than expected. WBA's Q4 earnings call showed a clear commitment to a turnaround, especially with management putting a focus on its core retail pharmacy business and planning to close 1,200 unprofitable stores. I believe WBA stock has bottomed out and am upgrading my rating to Hold, but I'm not willing to upgrade further until a more careful review of the company's 10-K.

Walgreens: Cautious Optimism After Earnings (Rating Upgrade)

Retail pharmacy giant Walgreens Boots Alliance (NASDAQ:WBA) was on a long downward slide long before 2024 began.

This High-Yield Dividend Stock Just Soared 15%. Time to Jump on Board?

Every once in a while, a major brand name and its stock's existence are challenged. Often, the price action and the threatening state of the company are justified, and the business does end up going under.

Big Potential Brewing – Will Walgreens Deliver a Rally?

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported fourth-quarter fiscal year 2024 sales of $37.55 billion on Tuesday.

Walgreens Boots Alliance Analysts Expect Strategic Plans Will Boost Investor Confidence In 2025

Walgreens Boots is currently going all out to reform its pharmacy model by aggressively liquidating its unprofitable stores and businesses.

WBA Stock Up 16% on New Restructuring Strategy: How to Play the Stock

Walgreens is targeting to close approximately 1,200 stores over the next three years, with 500 of those closures happening in the 2025 fiscal year, the drugstore company told Fast Company.

Walgreens plans to close 1,200 stores, with 500 locations shuttering in the next year

It isn't easy to be positive on the struggling company's prospects.

1 Wall Street Analyst Thinks Walgreens Boots Alliance Stock Is Going to $16. Is It a Sell?

Walgreens plans to close 1,200 stores, impacting 13.79% of its total locations, to restructure and improve financial health. Despite beating Wall Street estimates, Walgreens' adjusted operating income fell 38%, and adjusted EPS dropped to $0.39 from $0.67 a year ago. The company's financials have been weak, with negative free cash flow and inconsistent performance, making it a risky investment.

Walgreens: A Turnaround Stock To Avoid

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q4 2024 Earnings Call Transcript October 15, 2024 8:30 AM ET Company Participants Tiffany Kanaga - VP of Global IR Tim Wentworth - CEO Manmohan Mahajan - Global CFO Mary Langowski - President, US Healthcare Conference Call Participants Lisa Gill - JPMorgan Ann Hynes - Mizuho Group George Hill - Deutsche Bank Charles Rhyee - TD Securities Eric Percher - Nephron Research Kevin Caliendo - UBS Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Partners Stephanie Davis - Barclays Operator Good day, ladies and gentlemen. Thank you for standing by.

Walgreens Boots Alliance, Inc. (WBA) Q4 2024 Earnings Call Transcript

Walgreens reports better-than-expected earnings and revenues in the fourth quarter of fiscal 2024.

WBA Stock Up on Q4 Earnings & Revenues Beat, Unveils Strategic Action

Walgreens Boots Alliance is undertaking a transformation focused on its retail pharmacy business in response to persistent challenges in the consumer market and pharmacy sector. As part of this strategy, the company plans to close approximately 1,200 underperforming stores in the next three years to streamline operations and increase profitability.

News for Walgreens Stock (WBA)